J&J says Tremfya meets primary and major secondary endpoints in axial PsA study
JNJ•Johnson & Johnson said Tremfya met the primary endpoint for BASDAI score improvement at week 24 and major secondary endpoints in an axial psoriatic arthritis study.
1. Study results
J&J said Tremfya met the primary endpoint for BASDAI score improvement at week 24 and major secondary endpoints for axial symptoms and MRI inflammation reduction. The company said the safety profile was consistent with psoriatic arthritis, with no new safety signals.
